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ABSTRACT 
A NAD+ analogue has been synthesised and incorporated into a folded polypeptide with 
a helix-loop-helix motif by a site-selective self-functionalisation reaction. The success 
of the incorporation reaction was shown by electrospray mass spectroscopy and two-
dimensional NMR spectroscopy. The solution structure of the polypeptide was not 
affected by the incorporation of the cofactor model as shown by NMR and CD 
spectroscopy. The rate of reduction of the peptide-bound NAD+ analogue by sodium 
dithionite and its stability in aqueous solution were compared to that of free 1-
methylnicotinamide. The peptide-bound NAD+ analogue was reduced faster and its 
lifetime was increased by more than a factor of three. The modified peptide is water 
soluble which is a requirement for the creation of a turnover system. 
NP-42, a 42-residue polypeptide, has been designed to bind substrates for a NADH-
mediated reduction reaction by the introduction of binding residues in a reactive site. 
NP-42 has been synthesised and the NAD+ analogue has been incorporated by a site-
selective self-functionalisation reaction as shown by ES-MS. 
PP-42, a 42-residue polypeptide, has been designed to bind pyridoxal phosphate, or a 
synthetic analogue of pyridoxal, by the introduction of binding residues in a reactive 
site. PP-42 has been synthesised and found to bind pyridoxal phosphate covalently as 
an aldimine as shown by UV spectroscopy and the appearance of a peak in the mass 
spectrum corresponding to the molecular weight of the peptide-bound pyridoxal 
phosphate. 
Preparations have been made for the synthesis of a cyclic hexapeptide containing a 
pyridoxal residue, for use as a transaminase mimic. 
Keywords: NAD+, NADH, enzyme mimic, folded polypeptides, transamination, 
pyridoxal, design, site-selective, self-functionalisation, incorporation. 
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1. Introduction. 
The catalytic function of many enzymes is dependant on the incorporation of cofactors1 
that have functionalities not otherwise available to the enzyme. The NAD7NADH 
cofactor couple, i.e. the oxidised and reduced forms of nicotinamide adenine 
dinucleotide, is the hydride-transfer reagent found in the dehydrogenase class of 
enzymes, that catalyse reduction reactions of carbonyl compounds, and oxidation 
reactions also, in metabolic systems2. NAD+ functions as a hydride acceptor, whereas 
NADH functions as a hydride donor. The cofactor is non-covalently bound to the 
enzyme in the active site, and is capable of transferring the hydride stereospecifically. In 
the alcohol dehydrogenases the substrate is bound in the active site by coordination to a 
zinc ion in a hydrophobic pocket, Figure 1. The zinc ion also has an important role in 
the transition state of the hydride transfer reaction. The NAD7NADH-dependent 
enzymes have been the targets of many enzyme mimics capable of stereoselective 
reduction of carbonyl compounds. 
The interest in enzyme mimics3, such as the cofactor-dependent enzyme mimics, is due 
to our interest in learning more about the structure-function relationships and 
mechanisms of the enzymes. There is also a need for novel catalysts capable of 
catalysing reactions not catalysed by native enzymes, and catalysts that are soluble in 
organic solvents or attached to inert polymers, while retaining their functionality. The 
cofactors are ideal for enzyme-mimicking studies in that they are readily available and 
easily modified4. 
1 Dug as, H. Bioorganic Chemistry, 3rd edition, 1996, Springer-Verlag, New York. 
2 Fersht, A. R. Enzyme Structure and Mechanism, 2nd ed.1985, W. H. Freeman, New York. 
3 Murakami, Y .; Kikuchi, J.-I.; Hisaeda, Y.; Hayashida, O. Chem. Rev., 1996, 96, 721. 
4 Metzler, A. E. Biochemistry, The Chemical reactions of Living Cells, Chap. 8. 1977, Academic 
Press, New York 
Ser 
Figure 1. Outline of the NAD+-substrate-zinc coordination. 
1 
Key features of enzymes targeted in enzyme mimickry include achieving reaction rate 
enhancements, substrate recognition, turnover, and stereospecific catalysis. An enzyme 
mimic with the properties of a native enzyme has not yet been achieved. 
These features are difficult to implement in model systems for several reasons. Reaction 
rate enhancements require the ability to bind the substrate in close proximity to the 
reactive part of the cofactor. The substrate recognition of enzymes is dependent on the 
three-dimensional structure of the reactive site, in many cases a hydrophobic crevice. 
Turnover requires a means of regenerating the catalyst after the first cycle is complete. 
Stereospecific catalysis requires the substrate to approach the cofactor in one, and only 
one, way. To achieve these features in enzyme mimics, cofactors are often coupled to 
organic template structures that are designed and synthesised to mimic one or more of 
the features mentioned above. The attachment of these template structure lowers the 
solubility of the cofactor in aqueous solution. Solubility in water is in many cases a 
requirement for a system to be capable of turnover. 
Catalysts capable of stereospecific hydride transferreactions have been reported to give 
enantiomeric excesses in the region of 95-98%. Metal ions have been incorporated, 
although the structure of the metal ion-substrate complexes remain unsolved. Substrate 
recognition has not been attempted. Turnover has not been reported and solubility is as 
problem, as most reported NAD7NADH-mimicking reactions are carried out in organic 
solvents such as acetonitrile or DMSO. 
Folded polypeptides have so far not been used in spite of the fact that they will ensure 
solubility of the peptide-bound cofactor, they are large enough to allow the 
incorporation of groups capable of substrate recognition and transition state binding. 
The exposed residues of polypeptides may be varied by minor modifications of the 
amino acid sequence that leave the tertiary structure unchanged. The catalytic groups 
available to enzymes are also available to polypeptides. 
This thesis presents the first examples of polypeptide-based cofactor model systems. 
These model systems have been designed with the future development towards 
turnover-capable systems in mind.The design of the model systems have been done 
from a thematic structure-function viewpoint, mimicking the structure of the active sites 
of relevant enzymes as closely as possible. 
2 
H2N 
2. The NAD+/NADH cofactor and model systems. 
The dehydrogenase class of enzymes perform redox reactions in metabolic systems' by 
utilising the NAD7NADH cofactor couple for hydride-transfer reactions, Figure 2. 
NH2 
•rW °H o o© o, o® 
o 
HO OH 
Figure 2. Nicotinamide adenine dinucleotide, NAD+. 
The residue responsible for the catalytic activity is the nicotinamide moiety, which 
exists in two redox forms, Figure 3. 
O 
pi 
Figure 3. The active moiety of NAD7NADH. R = adenine nucleotide. 
The reduced cofactor (NADH) can deliver one of the hydrons in 4-position of the 
nicotinamide residue as a hydride ion to a carbonyl group and reduce it to the 
corresponding alcohol. In the reverse reaction, the oxidised form of the cofactor 
(NAD+) can abstract a hydride from a substrate in an oxidation reaction[refj. The 
hydrogens at position 4 in the NADH dihydropyridine ring are prochiral5, Figure 4. 
H«> Pro 
Figure 4. The prochiral 4-hydrogens of NADH. 
5 see reference 2, p 226. 
3 
The transfer of a hydride ion from NADH to a substrate, or from a substrate to NAD+, 
is direct and stereospecific6. In the L-dehydrogenases, the hydride transfer proceeds 
from Hr via a si-face attack to produce products of S configuration. 
The alcohol dehydrogenases are metalloenzymes that utilise zinc ions for their 
catalysis7. The Zn2+ -ion is situated at the bottom of a hydrophobic pocket that joins the 
catalytic site with the nucleotide-binding part, Figure 5, and is bound to the enzyme by 
two cysteine residues and a histidine. A water molecule in the free enzyme 
is bound by the Zn2+ -ion and a serine residue in the free holoenzyme. The water is 
displaced by the substrate in the enzyme-substrate complex, Figure 6. 
6 Fischer, H. F.; Conn, E. E.; Vennesland, B.; Westheimer, F. H.; J. Biol. Chem. 1953, 202, 687. 
7 Brändén, C.-L; Jornvall, H.; Eklund, H.; Furugren, B. The Enzymes , 1975,11, 104. 
NAD+-binding 
cavity 
Substrate binding 
cavity 
Figure 5. Sketch of the active site of HLADH apoenzyme. 
4 
Cys-174 
' N ^ N H  His-67 
Cys-46 
Ser-48 
Figure 6. Outline of the ternary complex in HLADH. 
L-Lactate dehydrogenase lacks the Zn2+ ion in the active site, and its role is taken over 
by His-195 and Arg-1098, Figure 7. Arg-171 binds the carboxylate residue of the 
substrate. The role of His-195 is to deprotonate the alcohol and together with Arg-109 
R-N.© /)—H 
Arg-171 i 
HN 
H2N^NH2 
O ®o 
H-j-O-H 
CH3 
\ Asp-168 
© O 
H His-195 
/f-N' 
N 
H2N© NH2 
Arg-109 f 
Y 
NH 
Figure 7. Sketch of the active site of LDH. 
8 Parker, D. M.; Holbrook, J. J. Pyridine Nucleotide Dependent Dehydrogenases, 1977, Sund, H. (ed), 
Walter de Gruyter, Berlin, p 485. 
stabilise and bind the alcoholate anion. The hydride ion is then delivered 
stereospecifically to the R face of the NAD+ moiety, Figures 8 and 9. 
Arg-171 
H2N © NH2 
r-n: +7^ 
© o 
Asp-168 
N 
ch3 N 
hn®,nh2  
Arg-109 |^NH 
-^N'H His-195 
Figure 8. The stereospecific hydride transfer in LDH. 
Arg-171 J HN' 
H2N^NH2 Cq\) 
h2n 
Asp-168 
>=o 
©. 
R-0>h °T° n^N'H His-195 \=/ H Ln H~N.<±L 
CH3 \ 
hn®,nh2  
Arg-109 |^NH 
Figure 9. Structure of the ternary complex of LDH after hydride transfer. 
The stereospecific transfer of the hydride ion is the basis for the stereospecificity of the 
dehydrogenases. 
Model systems designed to mimic dehydrogenase activity must be able to incorporate 
some of the control mechanisms used for stereospecificity. 
To achieve this in enzyme mimics, an alternative way of imposing the required three-
dimensional restrictions upon the hydride transfer must be found. In the system of a 
6 
simple chiral NAH derivative interacting with ethyl benzoylformate, there are four 
possible interactions leading to hydride transfer, Figure 10. The si-face attacks both 
yield the (jR)-mandelate as product, and the re-face 
Figure 10. The four possible interactions between leading to hydride transfer. R* is 
the chiral functionality. 
attacks yield the (S)-mandelate. In order to achieve stereocontrol, all interactions but 
one must be disfavored. The enzyme mimic must allow the substrate to approach and 
interact with the NAD7NADH moiety by one of these pathways. 
The NAD7NADH system has been modelled extensively9. Studies of NAD+ model 
systems for mechanistic purposes has been done since 1951, when Westheimer10 and 
co-workers studied the mechanism of hydride transfer by using deuterium as a tracer to 
investigate the mechanism of NAD+-mediated ethyl alcohol oxidation to acetaldehyde. 
Later on, Westheimer studied the reduction of malachite green and methylene blue by a 
simple NADH cofactor model, BNAH, Figure 1110b. 
9 Yasui, S.; Ohno, A. Bioorg. Chem. 1986, 70. 
10 a) Westheimer, F. H.; Fisher, H. F.; Conn, E. E.; Vennesland, B. J. Am. Chem. Soc. 1951, 73, 
2403. 
b) Westheimer, F. H.; Mauzerall, D. J. Am. Chem. Soc. 1955, 77, 2261. 
si-face attack re-face attack 
re-face attack si-face attack 
7 
o 
N    
NH2 
Figure 11. The NAD+ model system BNAH 
Ohno and co-workers have shown that in e.g BNAH reductions of ethyl 
benzoylformate in acetonitrile, the reaction does not proceed unless an equimolar 
amount of Mg2+ ion is present11, and that the reaction rate of the reduction of 
trifluoroacetophenone is dependent on the concentration of Mg2+ ion12. 
van Eikeren and co-workers reported rate enhancements in the reduction of TFAB by 1-
n-propylnicotinamide (PNAH) of a factor of 5000 when changing the reaction medium 
from DMSO to water13. 
The Hantzsch14 1,4-dihydropyridine esters were capable of reducing organic 
compounds via a hydride transfer mechanism, Figure 12. 
The Hantsch ester was reported to reduce puruvic acid nonenzymatically, albeit in low 
yield. 
In attacking the problem of cofactor stability at low pH, Shinkai and co-workers 
replaced the pyridine ring by a quinoline derivative in order to enhance stability under 
acidic conditions15, Figure 13. This model was 
11 Onishi, Y.; Kagami, M.; Ohno, A. J. Am. Chem. Soc. 1975, 97(10), 4766. 
12 Ohno, A.; Yamamoto, H.; Oka, S. J. Am. Chem. Soc. 1981, 103, 2041. 
13 van Eikeren, P.; Grier, D. L. J. Am. Chem. Soc. 1975, 98, 4655. 
14 a) Braude, E. A.; Hannah, J.; Linstead, R. J. Chem. Soc. 1960, 3249. 
b) Braude, E. A.; Hannah, J.; Linstead, R. J. Chem. Soc. 1960, 3257. 
c) Norcross, B. E.; Klinedinst, Jr., P. E.; Westheimer, F. H. J. Am. Chem. Soc. 1962, 84, 979. 
15 Shinkai, S.; Hamada, H.; Manabe, O. Tetrahedron Lett. 1979, 16, 1397. 
H3C N" CH3 
Figure 12. A Hantsch ester. R = alkyl 
8 
o 
NH2 
Figure 13. The acid-stable quinoline-based NADH model of Shinkai. 
used in the synthesis of a-amino acids from a-keto acids. 
Others have worked on the stereochemical selectivity of the reaction. Meyers16 attached 
a glyoxylic acid residue to a modified cofactor analogue, Figure 14, and made the Zn2+-
mediated hydride transfer reaction intramolecular. The intramolecularity had the 
advantage of not only inducing stereoselectivity, but also enhancing the reaction rate 
considerably. 
An example of stereochemical control through substrate binding rather than through the 
formation of a NADH-metal ion-substrate complex is the cyclodextrine-based NADH 
model system, Figure 15, investigated by Toda and co-workers17. These analogues 
gave significant rate enhancements in the 
16 Meyers, A. I.; Brown, J. D. J. Am. Chem. Soc. 1987,109, 3155. 
17 Yoon, C.-J.; Ikeda, H.; Kojin, R.; Ikeda, T.; Toda, F. J. Chem. Soc., Chem. Commun. 1986, 
1080. 
Figure 14. The intramolecular NADH model used by Meyers. 
9 
Q 
O N 
NH2 
Figure 15. The cyclodextrine-bound NADH model of Toda. 
reduction of ninhydrin in comparison with that in the reduction by NADH. 
Another approach to the problem of inducing chiral selection in a NAD+/NADH model 
system was the introduction of C2 and D2 symmetry by Wennerström and co­
workers18. The C2-symmetric NADH model, Figure 16, reduced methyl 
benzoylformate in DCM with an e.e. of 95 %. 
Figure 16. The C2-symmetric NADH model used by Wennerström et al. 
These model systems have all attempted to mimic some aspect of the dehydrogenases. 
Partial solutions to the problems of stereoselectivity, metal coordination, and rate 
enhancements were proposed. The problem of achieving a turnover-capable system has 
so far not been solved, probably because most NAD7NADH mimics are insoluble in 
water. The most efficient way of regenerating the reduced form of the cofactor, by 
sodium dithionite, requires water as solvent. 
18 a ) Skog, K.; Wennerström, O. Tetrahedron Lett. 1992, 33, 1751. 
b) Skog, K.; Wennerström, O. Tetrahedron 1994, 50, 8227. 
c) Skog, K.; Wennerström, O. Tetrahedron Lett., submitted for publication. 
10 
3. The pyridoxal cofactor and model systems. 
The cofactor pyridoxal phosphate (PPal) is an important factor in the metabolism of a-
amino acids19. PPal condenses with an amino acid to form a Schiff base aldimine, 
which is transformed into a ketimine through an allylic rearrangement. The ketimine is 
hydrolysed by water, to form pyridoxamine and a keto acid, Figure 17. 
.CH2OPO3H ,CH2OPO3H ;H2OPO3H 
proton 
transfer 
Figure 17. The reaction sequence of the pyridoxal- or pyridoxamine-mediated 
transamination. 
The reaction is performed by a class of enzymes known as aminotransferases that are 
essential for the biosynthesis of a-amino acids. The exception is L-glutamic acid, for 
which the nitrogen is provided by ammonia, through an NADH-mediated reductive 
amination of 2-oxoglutarate. In the aminotransferase catalysed reactions a proton from 
the solvent is incorporated at the Ca of the new amino acid20, and the ß hydrogen of the 
amino acid is not a participant in the reaction2'.The pyridoxal is initially bound 
covalently as an aldimine Schiff base to the enzyme22, and is then displaced by the 
substrate amino acid, under the formation of a new Schiff base as shown in figure 18. 
19 a) Snell, E. E.; di Mari, S. J. The Enzymes, 1976, 2, 335. 
b) Davis, L.; Metzler, D. E. The Enzymes, 1972, 7, 33. 
20 Hilton, M. A.; Barnes, Jr., F. W.; Enns, T. J. Biol. Chem., 1956, 219, 83. 
21 a) Meister, A. Nature (London), 1957,168, 1119. 
b) Sprinson, D. B.; Rittenberg, D. J. Biol. Chem., 1950, 184, 405. 
c) Gisolia, S. B.; Burris, R. H. J. Biol. Chem., 1954, 210, 109. 
22 Hughes, R. C.; Jenkins, W. T. Fischer, E. H. Proc. Natl. Acad. Sei. USA, 1962, 48, 1615. 
11 
h3n. .co2 
Enzyme 
«U ^CO 2 
Enzyme 
Figure 18. The binding of the substrate amino acid to the enzyme-bound pyridoxal. 
R = CH20P03H", R'= amino acid side chain. 
The reaction has been thouroughly investigated in aspartate aminotransferase23. The 
pyridoxal-bound substrate is stabilised through the interactions with two arginine 
residues, Arg-292 and Arg-386. The phenolic group is hydrogen-bonded to the 
hydroxyl of Tyr-225 while the pyridine ring nitrogen is hydrogen-bonded to Asp-222. 
The 5'-phosphate group is bound by several amino acid residues, including Arg-266 
and Ser-255, Figure 19. 
Arg-292 
H V 
nh2 
H2NV .N. 
Arg-386 
NH2 
HN-fo © © 
—/ NH2 °2^^y 2 /— 
N H2N— ' Lys-258 
Arg-266 H!i© °3po^V°X«h. 
ë hn^nh2 
S : 
H H 
r° ' / 0 0 
Ser
-
255 T Asp-222 
°tx Tyr-225 
Figure 19. Outline of the active site of aspartate aminotransferase. 
23 Kirsch, J. F.; Eichele, G.; Ford, G. C; Vincent, M. G.; Jansonius, J. N .; Christen, P. J. Mol. Biol., 
1984, 174, 497. 
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The PPal-based enzymatic transamination proceeds via an allylic rearrangement, where 
the Ca-H bond of the amoni acid is broken, and a new C-H bond at the 4'-carbon of the 
cofactor is formed. The proton used in the formation of the new C-H bond is not the 
same as the one abstracted at the Ca-carbon of the substrate. 
The C-H bond that is broken in the allylic rearrangement is in a conformation 
perpendicular to the pyridine ring-plane when abstracted23, Figure 20. 
Figure 20. The Ca-H bond is perpendicular to the pyridine ring plane. 
Non-enzymatic transamination24 of a-amino acids can occur in presence of free cofactor 
as well as with the holoenzyme, but with much lower rates and selectivities. In many 
cases metal ions (e.g. Al3+) accelerate the transamination25. 
Breslow26 '27 attached a cyclodextrine to pyridoxamine, by covalent bonding to the 5'-
hydroxy group, Figure 21. A large number of different organic structures have also 
been attached to pyridoxamines, and their potential as enzyme mimics evaluated26,27. 
24 Martell, A. E. Acc. Chem. Res., 1989, 22(4), 115. 
25 Martell, A. E.; Taylor, P. A. Inorg. Chim. Acta, 1988, 152, 181. Martin, R. B. Inorg. Chem. 
1987, 26(14), 2197. 
26 a) Breslow, R. Chemica Scripta 1987, 27, 555. 
b) Breslow, R.; Czarnik, A. W.; Lauer, M.; Leppkes, R.; Winkler, J.; Zimmerman, S. J. Am. 
Chem. Soc. 1986, 108, 1969. 
27 a) Breslow, R.; Czarnik, A. W.; Zimmerman, S. C. J. Am. Chem. Soc. 1983,105, 1694. 
b) Breslow, R. Ann. NY Acad. Sei. 471 (Int. Symp. Bioorg. Chem. 1985), 60. 
c) Weiner, W.; Winkler, J.; Zimmerman, S. C.; Czarnik, A. W.; Breslow, R. J. Am. Chem. Soc. 
1985, 107, 4093. 
d) Breslow, R.; Chmielewski, J.; Foley, D.; Johnson, B.; Kumabe, N.; Varney, M.; Mehra, R. 
Tetrahedron 1988, 44{ 17), 5515. 
e) Breslow, R.; Canary,, J. W.; Varney, M.; Waddell, S. T.; Yang, D. J. Am. Chem. Soc., 1990, 
112, 5212. 
H 
13 
H3C 
h2N~~S 
s 
Figure 21. The cyclodextrine derivative used by Breslow. 
Murakami and co-workers have attached pyridoxine moieties to vesicle bilayers28, and 
attempted to control the stereochemistry of the reaction. Small, 6-residue, polypeptides 
functionalised with pyridoxal and pyridoxamine have been use d for transamination 
studies by Imperiali et al29. 
Wu30 studied the reactivity of a pyridoxamine derivative with an attached propellane 
designed to function as a bifunctional catalyst, Figure 22. One nitrogen was expected to 
abstract a proton, and the other nitrogen was expected to donate a proton. The work by 
Wu was a thorough investigation of the inter- versus intra-molecularity of the proton 
transfer step in the aldimine-ketimine equilibrium of the transamination reaction. 
The propellane moiety functioned as proton abstractor and donor in the intramolecular 
transamination reaction, but no enhancements were observed, possibly due to 
coordination of the Zn2+ ion to the amine side chain. 
28Murakami, Y.; Kikuchi, J.-L; Akiyoshi, K.; Imori, T. J. Chem. Soc. Perkin Trans., 2 1985, 1919. 
29a) Imperiali, B.; Roy, R. S. J. Org. Chem., 1995, 60, 1891 
b) Imperiali, B.; Roy, R. S. Tetrahedron Lett., 1996, 37, 2129. 
30 a) Wu, Y.-K., Thesis, Göteborg University, 1991. 
b) Wu, Y.-K., Ahlberg, P. Acta Chem. Scand., 1992, 46, 60. 
Figure 22. The pyridoxamine derivative employed by Wu. 
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4. Outline of the model systems in the present investigation 
Folded polypeptides are good templates for the engineering of enzyme mimics. The 
peptide surface can be designed to incorporate similar functional groups as are present 
in the active site of the enzyme. The functional groups in the reactive site can be varied 
systematically by changing amino acid residues in the sequence to optimise binding and 
reactivity. Folded polypeptides are soluble in water, and the solubility is not effected by 
the incorporation of e.g. a NAD7NADH analogue. Solubility is in some cases a 
requirement for the creation of a catalyst capable of turnover. Polypeptides are readily 
available due to the advanced state of solid phase peptide synthesis technology. 
RA-42 is a 42-residue polypeptide that folds into a helix-loop-helix motif which 
dimerises in solution into an amphiphilic antiparallel dimer31. RA-42 was found to react 
rapidly and site-selectively with mono-p-nitrophenyl fumarate to form an amide at the 
side chains of lysine and ornithine residues32. This reaction was used for the 
incorporation of a nicotinoyl moiety in an attempt to create a NAD7NADH model as a 
first step towards peptide-based enzyme mimics. 
An alternative approach is the use of cyclic hexapeptides as templates. They have well-
defined structures and are straightforward to synthesise and purify. The incorporation 
of a pyridoxal derivative, functionalised as a diamino acid derivative, in a 
cyclohexapeptide is expected to result in a transaminase mimic, which can be designed 
to bind amino acids stereoselectively and to organise catalytic groups in a predetermined 
reactive geometry. 
31 Lundh, A.-C., Thesis, Göteborg University, 1995. 
32 Broo, K., Thesis, Göteborg University, 1997. 
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5. Polypeptide design, structure, and reactivity. 
5.1. Rational design of polypeptides 
The interest in de novo design of polypeptides with well-defined tertiary structures 
stems from the importance of protein folding. By design and study of small 
polypeptides, with less than 100 residues, the understanding of protein folding 
mechanisms can be enhanced. The design of tailor-made proteins for catalysis and 
recognition is therefore. It is now possible to design small polypeptides that have well-
defined tertiary structure and introduce catalytic functions, and a small number of 
polypeptides with such properties has been reported. 
5.2. Design and structure of SA-42 and RA-42 
SA-4233, a polypeptide with 42 amino acid residues, was previously designed to fold 
into a helix-loop-helix motif that would dimerise in solution to form a four-helix 
amphiphilic antiparalell bundle. The design of the helical system was based on amino 
acids with helix propensity34,35. Helical dipole stabilisation36 and capping, as well as 
salt bridge formation was used to further stabilise the helices. A loop between the two 
helical segments was designed by the introduction of amino acids with helix-breaking 
properties. Hydrophobic interactions between amino acid side chains was the driving 
force in the stabilisation of the helical structure and dimerisation37. The hydrophobic 
core contained phenylalanine, leucine, isoleucine and norleucine residues. The amino 
acid sequence was varied and included 16 different amino acids, in order to facilitate 
structural investigation and resonance assignment by NMR spectroscopy. Two 
phenylalanine residues were placed at the end of helix II, to yield chemical shift 
dispersion and to function as NOE reporter. Studies of SA-42 in solution by both NMR 
and CD spectroscopy as well as by ultracentrifugation revealed that it does form an 
amphiphilic helix-loop-helix motif that dimerises in an antiparalell fashion. 
A reactive site for ester hydrolysis was included on the surface of the folded SA-42, 
using His-15, Lys-19, Gln-26, and Gln-30. The reactive site was positioned close to 
the ß-turn in the hairpin motif. The reactive site however did not enhance the rate of the 
ester hydrolysis beyond that of the 4-methylimidazole catalysed reaction 
33 Olofsson, S., Thesis, Göteborg University, 1994. 
34 O'Neil, K. T.; DeGrado, W. F. Science, 1990, 250, 669. 
35 Chou, P.Y.; Fasman, G. D. Biochemistry, 1974,13, 222. 
36 Hol, W. G. J.; van Duijnen, P. T.; Berendsen, H. J. C. Nature, 1978, 273, 443. 
37 a) Kellis, Jr. J. T., et al. Nature, 1988, 333, 784. 
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The studies of Lundh31 led to the design and synthesis of RA-42, a 42-residue peptide 
which performs acyl transfer reactions of activated esters. The structural basis of RA-42 
was the hydrophobic core of SA-42, but the reactive site was moved towards the 
middle of the motif, in order to transfer it from the less stable helix ends. In RA-42 
ornithine residues were introduced, to replace the glutamine residues of the reactive site 
of SA-42, in order to enhance the hydrolytic capacity of the peptide. The reactive site of 
RA-42 was designed with a histidine residue at position i (His-11) and an ornithine 
residue in position i+4 (Orn-15), Figure 23. 
The purpose of the design was to obtain a reactive center with a nucleophilic catalyst, 
the imidazolyl group of the histidine, and a flanking positively charged hydrogen bond 
donor that could bind the acyl residue as an amide. 
5.3 The reactivity of RA-42 and LA-42. 
RA-42 reacted with mono-p-nitrophenyl fumarate in 10 % TFE at pH 5.85 and 293 K 
under the release of p-nitrophenol with a second-order rate constant of 28* 10"3 dm" 3  
mol"1 s '1 which is 8.3 times larger than the the second-order rate constant of the 4-
methyl-imidazole catalysed reaction, 3.38* 103 dm"3 mol"1 s"1. The reaction was studied 
over a range of pH, in order to identify the reactive residues. The pH profile of the 
reaction showed that the histidine was the catalytically active amino acid. The reaction 
products were identified by NMR spectroscopy and mass spectroscopy and it was 
found that the acyl group of the substrate formed an amide of the side chain of an Orn 
or a Lys residue. 
The acyl transfer reaction proceeds via the initial and rate determining formation of an 
acyl intermediate under the release of p-nitrophenol. In the next step the acyl group is 
transferred in a fast intramolecular transfer to the flanking ornithine residue. 
b) Chotia, C. Nature, 1974, 248, 338, 
H 
s/vv > ^ /\y\/\y\/\/vv\/v'v/\z^ 
i+4 
Figure 23. Outline of the reactive site of RA-42 
17 
5.4. The site selectivity of RA-42. 
There are three residues in RA-42 with side chains that can form amide bonds, Orn-15, 
Lys-19 and Orn-34. Orn-15 was the final recipient of the acyl group. Broo32 established 
that in RA-42 one equivalent of fumarate acylates only Orn-1538 by trypsin-catalysed 
site-selective cleavage of the acylated peptide and identification of the fragments by ES-
MS. The same results were observed by NMR spectroscopy. The reaction was found to 
be site-selective and only residues in position i+A or i-3 relative to the histidine in 
position i were shown to be amidated. 
The proposed reaction sequence for the acyl transfer reaction is shown in Scheme 1. 
HOpNP 
Scheme 1. Proposed reaction sequence for the acyl transfer reaction of RA-42 
5.5. NAD+ analogue incorporation into RA-42 and LA-42. 
In order to exploit the functionalisation reaction in cofactor incorporation, a 
NAD7NADH cofactor analogue was synthesised. The system chosen was a p-
nitrophenyl ester of iV-methylnicotinic acid, Figure 24. Initially, 
38 Broo, K.; Allert, M.; Andersson, L.; Erlandsson, P.; Stenhagen, G.; Wigström, J.; Ahlberg, P.; 
Baltzer, L. J. Chem. Soc. Perkin Trans. 2,1997, 397. 
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0JCT 
r© 
CH3 
Figure 24. The p-nitrophenyl ester of N-methylnicotinic acid. 
RA-42 was used, but then LA-42 was used because it was slightly more reactive. The 
only difference between RA-42 and LA-42 is that Orn-15 in RA-42 has been replaced 
by a lysine. The modified LA-42 was studied with NMR and CD spectroscopy in order 
to determine the effect of the modification on the secondary and supersecondary 
Once the NAD+ moiety was incorporated into the peptide structure, its reduction was 
attempted. A survey of the literature showed that this would most conveniently be 
accomplished through a reduction with sodium dithionite in the presence of sodium 
carbonate39. For comparison, two model systems were used, 1-methylnicotinamide and 
Ne-(iV-methyl-nicotinoyl)-ornithine, Figure 25. 
structure. 
O O 
Figure 25. The model systems used in the comparison reactions 
39 Blankenborn, G.; Moore, E. G. J. Am. Chem. Soc. 1980,102, 1092. 
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6. The design and structure of the peptides NP-42 and PP-42. 
6.1. Design of NP-42 
With the successful incorporation and reduction of the NAD+ analogue into LA-42, the 
next logical step was the design of a polypeptide to be used as a dehydrogenase mimic. 
The design of NP-42 was based on the structure of RA-42. The hydrophobic core of 
RA-42 was kept unchanged, whereas the active site was moved towards the amino- and 
carboxy-terminii, away from the loop, in order to increase the surface area of the 
peptide on which to place side chains for substrate and transition-state binding. As a 
structural model for this reactive site, lactate dehydrogenase (LDH) described by 
Adams40 was used, Figure 26. 
Arg-171 
HN^ \ 
H2N^NH2 
w ün 
Asp-168 
°%° H 
^•N- »is-195 
^0 
H2N^,nh2 
Arg-109 ^NH 
Figure 26. Sketch of the active site of lactate dehydrogenase, LDH. 
There are two main differences between the reactive site of the designed peptide and the 
active site of LDH.The active site of LDH is situated within a hydrophobic pocket in the 
enzyme whereas the reactive site of NP-42 is situated on the surface of the peptide, and 
the number of positions available for amino acid side chains on NP-42 is much smaller 
than in LDH. The amino acid sequence of NP-42 is shown in Figure 27. The 
underscored residues are designed to be parts of the reactive site. To keep the reactive 
site design as simple as 
4n Adams, M. J. E nzyme Mechanisms, Page, M. I.; Williams, A. (Eds.), 1987, Royal Soc. Chem. 
London. 
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Asn-Ala-Ala-Asp-Nle-Glu-His-Ala-He-Arg-Lys-Leu-Ala-Glu-Arg-Nle-Ala-Ala-Gly-
1 7 11 15 19 
-Gly-Pro-V al-Asp-
20 23 
G1y-A1a-Arg-Ala-Phe-Ala-Glu-Phe-Arg-Arg-Ala-Leu-Arg-Glu-Ala-Nle-Gln-Ala-Ala 
42 34 30 24 
Figure 27. The amino acid sequence of NP-42. 
possible, arginine residues were chosen both for substrate binding and transition state 
stabilisation, and as a proton donor in the carbonyl reduction reaction. The positioning 
of the residues is as shown in Figure 28. 
J Arg- 15 
HN 
H2N@*NH2 
Lys-11 
H2N H Arg-30 ©W-H2N 
H2N^.nh2 
NH 
Arg-34 
Figure 28. Suggested reactive site structure of NP-42 according to presynthetic 
molecular modelling studies 
In the designed model Lys-11 is the residue which carries the incorporated 1,4-
dihydronicotinamide moiety, and Arg-15 binds the carboxylate residue of the substrate. 
Arg-30 and Arg-34 can also be used for binding the substrate. The Aib residues used in 
RA-42 were replaced by alanines in NP-42. 
6.2. Design of PP-42 
In widening the scope of polypeptide-based enzyme mimics a transaminase mimicking 
peptide, PP-42, was designed. PP-42 is also based on the structure of RA-42. 
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Molecular modelling studies indicated that the positioning of the His-Lys reactive site at 
positions 7 and 11 would be the most advantageous in the design of a transaminase-
mimicking peptide. This positioning would, like in NP-42, increase the number of 
available side chains that would be used to make up the reactive site. 
In order to keep the pyridoxal ring parallel to the peptide plane, formation of an internal 
aldimine would be necessary. The reactive site was loosely modelled after the active site 
of aspartate transaminase41. Two 'extra' lysine residues, at positions 15 and 30, were 
introduced. They were positioned far enough from His-7 to ensure minimal possibility 
of diacylation and were used to maximise the possibility for intramolecular aldimine 
formation and to have one lysine function as base in the transamination reaction. Two 
arginine residues and a glutamic acid were also made part of the reactive site, to bind the 
cofactor and to bind in the transition state, Figure 29. 
Figure 29. Placement of amino acid residues in PP-42 according to molecular 
modelling studies 
Here, as in NP-42, the Aib residues were replaced by alanines. The amino acid 
sequence of PP-42 is shown in Figure 30, with the amino acid residues of the reactive 
site underscored. 
41 Smith, D. M.; Thomas, N. R.; Gani, D. Experentia, 1991, 1104. 
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Asn- Ala-Ala- Asp-Nle-Glu-His-Ala-Ile-Arg-Lys-Leu-Ala-Glu-Lvs-Nle-Ala-Ala-Arg-
1 7 11 15 19 
-Gly-Pro-V al-Asp-
20 23 
Gl v- A1 a - A rg-AI a-Phe-Ala-Glu-Phe-Glu-Arg-Ala-Leu-Ly s-Glu-Ala-Nle-Gln-Ala-Ala 
42 34 30 24 
Figure 30. The amino acid sequence of PP-42. 
Modelling studies of the distances between side chains suggested that a chain-elongated 
pyridoxal analogue would be a good choice for incorporation, as a longer side chain 
would increase the possibility for interaction with other groups in the reactive site. 
The incorporated pyridoxal analogue is supposed to form an internal aldimine, to either 
Lys-15 or Lys-30. An example of such an aldimine, between pyridoxal phosphate and 
Lys-15, is shown in Figure 31. 
N Arg-19 
H2N^nh2 
HN-
Glu-34 
Arg-24 
His-7 ^Nh2 / n 
z~Yy ho-vn. 
Lys-30 
Figure 31. Outline of a pyridoxal phosphate-Lys-15 internal aldimine of PP-42. 
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7. Design of the cyclic hexapeptide 
7.1. The cyclic hexapeptide structure 
The choice of a cyclic hexapeptide as the basis for design and synthesis of a 
transaminase mimic was based upon the need to control the stereochemistry and the 
distances between functional groups. Many cyclic hexapeptides have stable, well-
defined structures. The synthesis of hexapeptides is relatively short and the purification 
is straightforward. 
7.2 Design of the cyclic hexapeptide 
Many cyclic hexapeptides have a ß-turn-ß-turn conformation, Figure 32. 
A pyridoxine derivative can be incorporated as a bridge that restricts conformational 
degrees of freedom in the peptide. The outline of this peptide is shown in figure 33. 
The amino acids AA-3 and AA-6 are the residues that are coupled to the pyridoxine 
derivative. Arg-1 and His-2 can be used for either catalytic functions and Ser-4 and 
Arg-5 were incorporated to enhance solubility,. His-2 was designed to function as the 
proton abstractor and donator in the transamination reaction, whereas Arg-1 was 
Figure 32. Schematic conformation of a cyclic hexapeptide 
His2 AA3 Ser4 
Argi AA6 Arg5 
Figure 33. Outline of the designed cyclohexapeptide. 
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designed to bind to the carboxylate function of the substrate amino acid. The schematic 
structure of the designed cyclohexapeptide is shown in Figure 34. 
V 
NCH3 
Figure 34. Designed cyclohexapeptide based transaminase mimic. 
The protecting groups on the two amino acid residues of the pyridoxine derivative must 
be different if the the pyridoxine-amino acid moieties are to be coupled at different 
positions in the sequence of the peptide. When the first amino acid residue is 
deprotected and coupled the other must remain protected. 
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8. Design and synthesis of the cofactor model systems 
8.1. Design of the two-armed pyridoxine derivative for incorporation 
into a cyclohexapeptide 
In order to incorporate a structurally well-defined pyridoxine function into a cyclic 
hexapeptide linkages to the cyclic peptide had to be constructed. The length of the 
linkages was determined by molecular modelling and a three-carbon chain was found to 
be . The 2- and 5-positions of the pyridine ring were designated as attachment points 
for the linkages as they are not essential for reactivity. The coupling of the linkage 
chains to the amino acid moieties must be done sequentially in order to be able to use 
different protection groups for the two amino acids, and use of different protection 
groups on the two amino acid functions is required for sequential insertion into the 
amino acid sequence during the peptide synthesis. The structure of the designed 
pyridoxine derivative is shown in Figure 35. 
Figure 35. The designed two-armed pyridoxine derivative. R-R'" are different 
protecting groups 
8.2. Synthesis of a two-armed pyridoxine derivative for incorporation 
into a cyclic hexapeptide 
The synthetic sequence for the designed pyridoxine derivative was mainly based on 
methods published by Korytnyk42, Scheme 2. 
CH3 
42 a) Korytnyk, W. J. M ed. C hem., 1965, 8, 112. 
b) Korytnyk, W.; Srivastava, S. C.; Angelino, N.; Potti, P. G. G.; Paul, B. J. Me d. C hem., 1973, 
16, 1096. 
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<^C02H ... O .CHO 
"OH OH 
'OTBDPS 'OTBDPS "OTBDPS 
OH 
O .O .O 
"OTBDPS ii OTBDPS ii OTBDPS 
OHC 
HO 
Scheme 2. The synthetic path of the two-armed pyridoxine derivative. 
The synthesis started from the 3-0-oc4-isopropylidenepyridoxine43 by oxidation to the 
corresponding aldehyde using Mn02, (i). The aldehyde was then transformed to the 
a,ß-unsaturated acid through a Knoevenagel condensation with malonic acid, (ii). The 
unsaturated acid was reduced directly to the saturated alcohol by LiAlH4 in THF, (iii). 
The alcohol was protected as a tert-butyldiphenyl silyl ether through a DMAP-catalysed 
reaction44, (iv). Oxidation of the silyl ether at the pyridine nitrogen using MCPBA, (v), 
yielded the TV-oxide, which was transformed to the 2'-alcohol in a TFAA-mediated 
rearrangement, (vi). The 2'-alcohol was then oxidised with Mn02, (i), the formed 
aldehyde was condensed with malonic acid, (ii), and the formed unsaturated acid was 
reduced with LiAlH4, (iii), similarly to what was described for the 5-position. 
The resulting alcohol was then to be transformed into a halide and asymmetrically 
alkylated onto an amino acid moiety. The TBDPS protecting group would then be 
removed, and a second asymmetric alkylation performed to yield the designed 
derivative. 
8.3. Design of the pyridoxal derivatives for incorporation into PP-42 
In order to expand the cofactor incorporation concept to include transamination, two 
pyridoxal and one pyridoxamine derivatives were developed, Figure 36. 
43 Wu, Y.-K.; Ahlberg, P. Acta Chem. Scand., 1989, 43, 1009. 
44 Chaudhary, S. K.; Hernandez, O. Tetrahedron Lett., 1979, 99. 
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no2 
HO. 
Boc-N 
Figure 36. The three derivatives of pyridoxal and pyridoxamine designed for 
incorporation in PP-42 
The compounds were to be incorporated using the site-selective functionalisation 
reaction. 
8.4. Synthesis of the NAD+ model systems and NAD+ incorporation 
derivative 
The p-nitrophenyl ester of N-methylnicotinic acid, 2, Figure 37, was prepared in two 
synthetic steps. The first reaction was the esterification of nicotinic acid with p-
nitrophenol using DCC and pyrrolidinopyridine as coupling reagents45. The ester was 
methylated with methyl iodide in DMF. The product was used both for incorporation 
into the peptides and as reagent in the synthesis of 3, Figure 38. 3 was prepared by 
first making a copper chelate of L-ornithine and then adding the p-nitrophenyl ester 2 to 
the chelate. 
45 Hassner, A.; Alexanian, V. Tetrahedron Lett., 1978, 4475. 
CH3 
Figure 37. The p-nitrophenyl ester of yV-methylnicotinic acid, 2. 
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Figure 38. N£-(iV-methylnicotinoyl)-L-ornithine iodide, 3. 
3 was to be used together with 1-methylnicotinamide as a reference for comparisons of 
the rate of reduction and of stability. 
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9. Asymmetrie amino acid synthesis 
9.1. The Mutter approach to a-methylated a-amino acid synthesis 
The pyridoxine derivative designed for incorporation into the cyclohexapeptide was to 
be alkylated asymmetrically with two a-amino acid moieties. There are a large number 
of methods of amino acid synthesis in the literature that give both good chemical yields 
and products of high optical purity46. Those most suited to our purposes were the 
methods of Mutter47, Schöllkopf48, and Myers49. 
Figure 39. Mutter's Oxazolidinone method of asymmetric a-amino acid synthesis. 
R'=H or CH3. 
This synthesis according to Mutter, Figure 39, is rather straightforward, with the only 
apparent sensitive step being the enolisation of the oxazolidinione. The ring opening 
method shown in Figure 39 is the simplest of the alternatives, the other being catalytic 
hydrogénation. 
9.2. The Schoellkopf 6/s-Iactim ether method 
The Schoellkopf b/s-lactim ether method begins with the synthesis of an asymmetric 
bz's-lactim ether of either alanine and valine, or of glycine and valine. 
46 For two comprehensive reviews of asymmetric a-amino acid synthesis, see 
a) Williams, R. M., Synthesis of optically active a-amino acids, Vol. 7 of Organic Chemistry 
Series; Baldwin, J. E.; Magnus, P. D. (Eds); Pergamon Press, Oxford, 1989. 
b) Duthaler, R. O. Tetrahedron, 1994, 50, 1539. 
47 Altmann, E.; Nebel, K.; Mutter, M. Helvetica Chim. Acta, 1991, 74, 800. 
48a) Schöllkopf, U.; Hinrichs, R.; Lonsky, R. Angew. Chem. Int Ed. Engl. 1987, 26, 143. 
b) Schöllkopf, U.; Lonsky, R. Synthesis, 1983, 675. 
H2N^C02Na 
CH3 
1.PhCE 
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Figure 40. Schoellkopf s bis-lactim ether method. 
The «-lactim ether is alkylated, through the sequence shown in Figure 40, with a 
suitably active alkyl halide, yielding a trans product. After the alkylation, the bis-lactim 
ether is hydrolysed by acid to give an amino ester hydrochloride, or, if a stronger acid 
is used, an amino acid hydrochloride. 
9.3. The pseudoephedrine method of Myers 
The final method considered was the alkylation of the amino acid amides of 
pseudoephedrine, developed by Myers and co-workers49. The general outline of the 
method is given in figure 41. 
CH3 H CIOC—E- CH3 O U^n.c„3 • 1 UaNA.«Yv 
ÖH H 0 ET3N ÖH CH3 O 
H3O+ 
OJ-^ nh, . '5'^ "Li ÛJ^NH, 
ÖQ CH3 6H CH3 
I R-CH2-Hal 
CXJ*n\nh2 n°0h<50*) HX« -
ÖH CH3 OH H 
Figure 41. The Myers' pseudoephedrine synthesis of optically pure amino acids. 
49 a) Myers, A. G.; Bryant, H.; Yang, H. C.; Gleason,J. L. J. Am. Chem. Soc. 1994, 116, 9361. 
b) Myers, A. G.; Gleason, J. L.; Yoon, T. J. Am. Chem. Soc. 1995, 117, 8488. 
c) Myers, A. G.; Yoon, T.; Gleason, J. L. Tetrahedron Lett. 1995, 36, 4555. 
d) Myers, A. G.; Gleason, J. L. J. Org. Chem. 1996, 61, 813. 
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A variation of this method, using alanine instead of glycine, was also considered. 
In these methods the authors report obtaining optically pure amino acids in good yield 
by coupling of a glycine or an alanine with an auxiliary, to form a chiral derivative, 
deprotronation of this derivative with a strong base, and alkylation of the anionic 
intermediate. This preferentially occurs on one face of the glycine or alanine derivatives. 
Cleavage of the auxiliary from the amino acid residue produces the new optically pure 
amino acid. The optical purity of the products reported in the range of 95-99% e.e. and 
the chemical yields are between 70 to 90 %. 
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10. Results and discussion. 
10.1. Incorporation of a NAD+ analogue into RA-42 and LA-42 
RA-42 is a 42-residue polypeptide designed to fold into a helix-loop-helix motif and 
dimerise to form a four-helix bundle. Its solution structure has been determined by 'H 
NMR and CD spectroscopy and the formation of the helix-loop-helix motif has been 
established. Its helical content was determined by CD spectroscopy and its mean 
residue ellipticity at 222 nm was -18 800 deg cm2 dmol"1. 
RA-42 reacts with mono p-nitrophenyl fumarate in a second-order reaction under the 
release of p-nitrophenol to form an amide at the side chain of the flanking ornithine. 
LA-42 is a 42-residue peptide with a structure identical to that of RA-42 except that 
Orn-15 is replaced by Lys-15. 
RA-42 was reacted with a thirteenfold excess of the p-nitrophenyl ester of N-methyl 
nicotinic acid under in aqueous 50 mM sodium acetate buffer at pH 5.9 and 293 K. The 
reaction was monitored spectrophotometrically at 320 nm but the second-order rate 
constant for the release of p-nitrophenol was not determined due to precipitation in the 
cuvette. 
LA-42 was reacted with a thirteenfold excess of the p-nitrophenyl ester of //-methyl 
nicotinic acid in aqueous 50 mM sodium acetate buffer at pH 5.9. The amount of ester 
was calculated by comparing the pseudo-first order rate constants for the peptide 
catalysed reaction and the background reaction. In cases where the peptide is available 
only in small amounts, the pesudo-first order rate constant for the peptide is 
approximated from the concentration of peptide and the second order rate constant of 4-
methylimidazol multiplied by five. The products were analysed by ES-MS, and the 
transformed mass spectrum showed one peak with a molecular weight of 4509.35 D, 
corresponding to the mass of LA-42 (4390.10) plus the mass of /V-methylnicotinic acid 
(138.20) minus the mass of water (18.02). The incorporation of the nicotinoyl residue 
was successful and no diacylated product was found. A second peak, corresponding to 
the unreacted LA-42 was also present in the spectrum. The relative intensities indicated 
approximately 60-75 % conversion of the peptide and it was therefore reacted with a 
sixtyfold excess of the ester. The excess of substrate was estimated from the 
concentration of the unreacted LA-42 (approx. 0.24 mM) and the ratio of the calculated 
pseudo-first order rate constants (approx. 50). The modified LA-42, LA-42NAD, was 
purified by size-exclusion chromatography on a Sephadex G-25 fine column using 
0.1% TFA as the eluent. LA-42NAD was obtained in a yield of 70 % based on the 
amount of peptide used as starting material. The NMR spectroscopic investigations of 
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LA-42NAD showed no significant change in structure upon functionalisation, and the 
difference between the CD spectra of LA-42NAD and LA-42 was within the 
experimental error limits. 
10.2. Reduction of RA-42NAD and LA-42NAD into RA-42NADH and 
LA-42NADH 
RA-42NAD was treated with a tenfold excess of both sodium dithionite and sodium 
carbonate in 50 mM sodium phosphate buffer under a nitrogen atmosphere at 293 K 
and pH 7. The reduction was monitored spectrophotometrically at 340 nm. 1-
Methylnicotinamide and A^-(N-methylnicotinoyl)-L-ornithine were also reduced under 
similar conditions for comparisons of reduction rates and stabilities of the reduced 
species with those of RA-42NAD. The reaction rate of the reaction was difficult to 
determine, as precipitation of the red form occurred. Comparison of the stabilities 
indicated that the reduced form of LA-42NAD is approximately three times as stable as 
free 1-methyl-1,4-dihydronicotinamide. The ornithine derivative was also reduced, but 
the results were not reproducible. 
LA-42NAD was treated with a sixteenfold excess of sodium carbonate and sodium 
dithionite (1:1) in 5 vol% TFE in 50 mM sodium phosphate buffer in 90 % H20:10 % 
D20 (V/V) under nitrogen atmosphere at pH 7. The reduction was followed by 'H NMR 
spectroscopy, where the disappearance of the pyridine resonances at 8.10 and 9.19 
ppm was observed, in agreement with the UV spectroscopic results. A small amount of 
TV-methyl nicotinic acid was also present as an impurity, but was not reduced by the 
sodium dithionite. 
10.3. Reduction of TFAB by LA-42NADH 
A tenfold excess of a,a,a-trifluoroacetyl benzene (TFAB) was added to the reaction 
mixture described above, and the reduction was monitored by 19F NMR. The substrate 
appears as a singlet at 1920 ppm, and the reduction product as a doublet at -440 ppm. 
relative to TFE. The reduction of TFAB was insignificant compared to that 
accomplished by reported model systems''and comparable to the background reduction 
induced by sodium dithionite50. 
50 a) de Vries, J. G.; van Bergen, T. J.; Kellogg, R. M. Synthesis, 1977, 246. 
b) de Vries, J. G.; K ellogg, R. M. J. O rg. Chem., 1980, 45, 4126. 
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10.4. NAD+ incorporation into NP-42 
NP-42 was reacted with a thirteen fold excess of the p-nitrophenyl ester of TV-methyl 
nicotinic acid in aqueous 50 mM sodium acetate buffer at 293 K and pH 5.9. The 
products were analysed by ES-MS, and the transformed mass spectrum showed one 
peak with a molecular weight of 4635.3 D, corresponding to the mass of NP-42 
(4515.73) plus the mass of N-methylnicotinic acid (138.20) minus water (18.02). No 
diacylated product was found. A second peak, corresponding to the unreacted NP-42 
was also observed in the spectrum. 
10.5. Incorporation of pyridoxal phosphate into PP-42. 
PP-42 was reacted with PPal in 50 mM Bis-Tris buffer at pH 5.9, and the formation of 
the aldimine was monitored by UV spectroscopy. When the aldimine absorbance was 
much larger than that of the free pyridoxal, a sample was analysed by ES-MS. The 
transformed mass spectrume showed a peak at 4762,98 D, which corresponds to the 
mass of PP-42 (4533.71) plus the mass of pyridoxal phosphate (247.1) less the mass 
of water (18.02). A peak representing free PP-42 was also present in the mass 
spectrum, and the relative intensities indicated that approximately 25% of the peptide 
had been modified. 
10.6. Synthesis of the two-armed pyridoxine derivative 
To incorporate the pyridoxine derivative in a cyclic hexapeptide, a method of coupling 
the pyridoxine derivative to amino acid moieties was needed. Several methods of 
asymmetric synthesis of a-amino acids were tried. 
The oxazolidinone compound was prepared in modest yields, approximately 30 %. 
Attempts were made to utilise N-protecting groups other than Cbz, usine Alloc-Cl and t-
Boc-Cl. The r-Boc derivative was formed in small amounts, but could not be isolated. 
The Alloc derivative was not formed at all. The alkylation sequence failed to produce 
any significant amount of product. After several attempts, a 20 % yield of the n-pentyl 
alkylated oxazolidinone was isolated. 
Alkylation of the Z?/s-lactim ether was performed according to the literature[ref] and the 
yield was within the range reported in the literature. The work-up methods were not 
suitable to the functional groups required of the project. 
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The alkylations of the pseudoephedrine glycinamide proceeded according to the 
literature, but the alaninamide alkylations failed to produce any significant amount of 
product. 
10.7. Discussion 
The amino acid syntheses showed that preparing a pyridoxine derivative, functionalised 
with an amino acid moiety at the end of each of two elongated side chains, would be 
time-consuming as well as difficult, although the synthesis of the pyridoxine derivative 
itself was performed. The project was abandoned in favour of the post-synthetic 
modification of polypeptides. 
NAD7NADH model systems reported in the literature are mainly nicotinamides coupled 
to some form of organic structure that are introduced to induce stereoselective hydride 
transfer, rate enhancements, and substrate recognition. High degrees of stereoselectivity 
have been achieved in many cases by attaching the nicotinamide moiety to chiral 
auxiliaries51. High reaction rates have also been achieved15 in some cases, but not 
substrate recognition which has rarely been attempted. The introduction of organic 
template structures requires complex asymmetric syntheses in most cases, and the 
model systems are therefore often difficult to prepare. 
The NAD+ form of the cofactor is soluble in water, whereas the NADH form is less so. 
When an organic structure is attached to the cofactor its solubility in water is further 
decreased, and the reactions of these model systems are mainly studied in solvents like 
CH3CN, DCM, and DMSO. NADH-mediated hydride transfer reactions are slower in 
organic solvents than in water11. 
The use of folded polypeptides as template structures have many advantages. They are 
soluble in aqueous solutions, a likely requirement for the creation of NAD7NADH 
model systems capable of turnover. The solution structures of folded polypeptides can 
be solved by NMR and CD spectroscopy and polypeptides with well-defined 
supersecondary structures can be used to engineer reactive sites for binding and 
transition-state stabilisation by minor modifications of the amino acid sequence. The 
reactive sites of these peptides can the be systematically changed in order to optimise 
binding or introduce new functionalities. 
51 Burgess, V. A.; Davies, S. G.; Skerlj, R. T. Tetrahedron: Asymmetry, 1991, 2, 299. 
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We have now shown the potential of polypeptide-based enzyme mimics through the 
first reported successful site-selective self-functionalisation of a folded polypeptide with 
a NAD+ analogue and its subsequent reduction. Both the red and ox forms of the 
peptide-bound cofactor are soluble in water. The reduced form of the peptide-bound 
cofactor was also approximately three times as lomg-lived as the free 1-methyl-1,4-
dihydro-nicotinamide. Furthermore we have designed a peptide-based dehydrogenase 
mimic, NP-42, with a more complex reactive site where the NAD+ cofactor was also 
successfully incorporated. Further studies on the structure and reactivity are underway. 
Also, a transaminase mimic, PP-42, was designed and synthesised. The reactive site of 
PP-42 was designed to bind pyridoxal phosphate (PPal) both covalently and non-
covalently. Preliminary results show the covalent incorporation of PPal into PP-42, and 
further studies of this system are also being carried out. 
The design and study of enzyme mimics is a discipline that is both challenging and 
rewarding. The use of post-synthetic modifications of polypeptides that form stable 
structural motifs is a novel approach with great potential. The classic approach has been 
to modify peptides unselectively, by e.g. the alkylation or acylation of lysine residues, 
which results in di/poly-acylation of all available primary amines. The relative ease with 
which the compounds are prepared for incorporation, i.e. the esterification with p-
nitrophenol, makes this method extremely convenient and it also allows the 
incorporation of molecules that are not able to withstand the conditions of peptide 
synthesis. 
The advantage is not only the site-selectivity, but also the fact that the amide bond is 
likely to withstand most conditions that the peptide itself can. Furthermore, the process 
can be applied to almost any substrate molecule that has or can have a carboxylic acid 
functionality which can be esterified. The protocol also allows for design of a reactive 
site in close proximity to the self-functionalisation site, for use of the incorporated 
moiety in catalysis. This gives the method a wide utility and applicability. 
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11. Methods 
Presented here is a short overview of the methods used but a full account is, however, 
beyond the scope of this thesis. 
11.1. Peptide synthesis 
Solid phase peptide synthesis (SPPS) has now become a standard technique in peptide 
chemistry. The first amino acid of the sequence is coupled to a polymer resin via the 
carboxyl function, and the amino acids to be coupled are added one by one together 
with coupling reagents. After each coupling the rersin is washed to remove excess 
amino acid and coupling reagents and the ^/-protecting group is removed. The next TV-
protected amino acid is then coupled to the amino group of the previous amino acid. 
The process is repeated until the desired number of amino acids have been coupled to 
the growing peptide. The polypeptide is then cleaved from the polymer and the side 
chain protection groups are removed, see Scheme 2. 
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X = synthetic handle 
Coupling of first amino acid 
Cleavage of AAj's protecting group 
Coupling of second amino acid 
Repetition of coupling/ 
J deprotection steps 
i 
Scheme 3. Outline of the general SPPS protocol. 
In Scheme 3 has been presented an outline of the peptide synthesis, but the 
improvements and variations are many. Commonly used iV-protection groups are t-Boc 
( tert-butyloxycarbonyl )and Fmoc (9-fluorenylmethyloxycarbonyl). The main 
difference between f-Boc and Fmoc chemistry is that r-Boc is removed by strong acid, 
usually TFA, and Fmoc is removed by base. The peptide-polymer linkage must 
therefore be stable towards strong acids in the case of t-Boc chemistry and the peptide 
has to be cleaved from the resin with the use of liquid HF, which leads to a number of 
impurities and side reactions. The Fmoc protection groups are removed with piperidine, 
which allows the use of a peptide-to-polymer bond that is more easily cleaved than in 
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the t-Boc strategy. In the Fmoc protocol the peptide is cleaved from the polymer by 
TFA, which is less damaging to the peptide. 
In this investigation we have used a fully automated Fmoc SPPS protocol and a 
continuous-flow method. 
11.2. HPLC 
The mixture left after cleavage of the peptide from the polymer resin contains a lot of 
impurities like scavengers, remnants of protecting groups, cleavage reaction by­
products, and deletion peptides, i.e. peptides that are shorter than the desired peptide 
due to failure of one or more of the coupling steps of the synthesis, and it is necessary 
to purify the peptide. 
Synthesised peptides are readily purified by reverse-phase HPLC using isopropanol-
water mixtures as eluent. 
11.3. NMR spectroscopy 
In structure determinations of polypeptides there are many powerful tools, but the most 
versatile is NMR spectroscopy. This technique can be used to study dynamics, dimer­
monomer equilibria and three-dimensional structure. 
Routine one-dimensional 'H and 19F NMR experiments, 'H NMR NOESY (Nuclear 
Overhauser Spectroscopy), and TOCSY (Totally Correlated Spectroscopy) 
experiments have been used. In combination with ES-MS and CD spectroscopy they 
yield sufficient data for a three-dimensional structure to be determined. The NOESY 
experiment gives vital information about e.g. the structure of the hydrophobic core, 
whereas the TOCSY spectrum gives information of the different amino acid residues 
and their chemical shifts. 
11.4. CD spectroscopy 
CD spectroscopy has been used only for comparisons ofm the mean molar ellipticities 
of the synthesisied or modified peptides and of RA-42 or LA-42. 
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11.5. Electrospray mass spectroscopy 
Electrospray mass spectroscopy (ES-MS) is an excellent method for verifying the 
structure of a peptide. A solution containing the substance of interest is injected into the 
spectrometer through a capillary frit, where it is subjected to a high electric field, in the 
range of 10-20 kV. On the frit surface, charged micro droplets are formed and the 
solvent is removed by a counter current of inert gas. The ions, which now carry 
multiple charges, are accelerated in a magnetic field towards the mass analyser. The 
ions are then analysed, and their mass-to-charge ratio determined. The ES-MS spectrum 
shows series of peaks with the same m/z ratios, but carrying a different number of 
charges. These peaks are analysed after calibration and then transformed to give the 
molecular mass of the molecule. 
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12. Experimental 
12.1. General 
All glassware was washed thoroughly and oven-dried overnight at 150 °C or for 72 h at 
55 °C. All air- and moisture-sensitive reactions were carried out in dry glassware under 
a positive pressure atmosphere of dry nitrogen gas. All air- and moisture-sensitive 
substances were transferred using gas-tight hypodermic syringes and septa. All 
solvents and reagents were dried and purified according to standard methods52 when 
necessary, and otherwise used at commercial purity. Peptide synthesis was performed 
on a PerSeptive Biosystems Pioneer continuous-flow peptide synthesiser. All peptide 
synthesis chemicals and solvents were of the appropriate purity and were used at 
commercial purity. All buffer solutions were prepared from double-distilled water 
which was then filtered through a Millipore microfilter. All 'H and 19F NMR spectra 
were recorded on a Varian Unity 500 FT-NMR spectrometer (9.395 T), except the two-
dimensional experiments, which were performed on a Varian Unity 500 FT-NMR 
( 11.744 T) spectrometer. Melting points were determined on a Reichert hot-stage 
microscope and are uncorrected. Optical rotations were measured on a Perkin-Elmer 
241 Polarimeter using the sodium D-line. HRMS was performed on a VG ZabSpec FD 
High resolution mass spectrometer. Flash chromatography (FC) was performed on 
silica gel S (230-400 mesh, 0.032-0.063 mm). Kinetic UV spectroscopy were 
performed on a Varian Cary 1 Bio UV-visible or a Varian Cary 4 spectrophotometer. 
CD spectra were recorded on a JASCO J-270 spectropolarimeter in the range from 300 
to 190 nm. The instrument was calibrated with d-(+)-camphor sulphonic acid. 
12.2. Peptide synthesis and purification 
Synthesis of NP-42 
NP-42 was synthesised on Fmoc-Gly-PEG-PS resin (500 mg, 0.200 mmol/g 
substitution) with Fmoc-Gly attached. The entire synthesis was performed on a 0.100 
millimolar scale. Fmoc chemistry was used throughout the entire synthesis. The 
peptide-containing resin was washed with DCM and dried in vacuo.The dry peptide 
was cleaved from the polymer with TFA (4.5 mL) using thioanisol (0.10 mL) and 
ethanedithiol (0.15 mL) as scavengers. The gel was then filtered, separating the peptide 
from the polymer, and washed with DCM. The free peptide was then precipitated with 
52 Perrin, D. D.; Armarego, W. L. F. Purification of Laboratory Chemicals, 3rd ed. 1988, Pergamon 
Press. 
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diethyl ether, centrifuged, and the supernatant ether removed. The crude peptide was 
then dissolved in water and lyophilised. 
Synthesis of PP-42 
PP-42 was synthesised in the same manner as NP-42. 
Purification of NP-42 
NP-42 was purified on a Varian Star HPLC system, using a preparative-scale C8 
column. The solvent system used was 40 % isopropyl alcohol in a 0.1 % aqueous 
solution of TFA for the first run, and 38 % isoporopyl alcohol in in a 0.1 % aqueous 
solution of TFA for the second and final run. The collected fractions containing the 
peptide was lyophilised to yield the pure peptide. 
ES-MS: 4515.729 (calc: 4516.09 gmol4) 
Purification of PP-42 
PP-42 was purified on a Varian Star HPLC system, using a preparative-scale C8 
column. The solvent system used was 40 % isopropyl alcohol in a 0.1 % aqueous 
solution of TFA. The collected fractions containing the peptide was lyophilised to yield 
the pure peptide. 
ES-MS: 4533.71 (calc: 4532.13 gmol1) 
12.3. Syntheses 
NAD+ analogues and model systems 
Nicotinic acid p-nitrophenyl ester (1) 
This substance was prepared according to methods reported in the literature41. Nicotinic 
acid (0.522 g, 4.06 mmol), DCC (0.965 g, 4.68 mmol), and p-nitrophenol (0.650 g, 
4.67 mmol) were dissolved in DCM (35 mL) and stirred at ambient temperature. 4-
Pyrrolidinopyridine (63 mg, 0.4 mmol) in DCM (4 mL) was then added dropwise, 
causing the solution to turn yellow. The reaction mixture was stirred for six days at 
ambient temperature, after which it was washed with dilute HCl (aq, 1.1 M, 4 mL) and 
filtered to remove precipitated DCU. The filtrate was washed with HCl (30 mL, 0.4 M) 
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and H20 (50 mL), dried (Na2S04), and the solvent removed in vacuo to yield the crude 
product. After recrystallisation from ethanol colourless needles were recovered in 92% 
yield (0.912 g). 
Mp: 171 °C 
'H NMR (400 Mhz, CDC13) 5 9.41 (s, 1H), 8.91 (d, 1H), 8.47 (d, 2H), 8.36 (d, 2H), 
7.51 (m, 1H), 7.45 (dd, 2H) 
N-Methylnicotinic acid p-nitrophenyl ester (2) 
This synthesis was prepared according to methods found in the literature53, p-
Nitrophenyl nicotinate (0.912 g, 3.74 mmol) was dissolved in DMF (5 mL), and 
methyliodide (0.798 g, 5.62 mmol) was added. The reaction mixture was stirred in 
darkness for six days at ambient temperature. The solution turned red, probably due to 
oxidation of the iodide ion. The product was precipitated by the addition of diethyl ether 
(200 mL). The yield was almost quantitative. 
'H NMR (400 Mhz, DMSO) 8 9.81 (m, 1H), 9.26 (d, 1H) 9.18 (d, 1H), 8.44 (d, 
2H), 8.35 (t, 1H), 7.71 (d, 2H) 
FAB-MS: 259 gmol"' (calculated: 259.072) 
iV£-(7V-inethyInicotinoyl)-L-ornithine iodide (3) 
This substance was prepared using methods reported in the literature54. L-Ornithine 
hydrochloride (0.40 g, 2.3 mmol) was dissolved in boiling water (50 mL. Copper 
carbonate (5.1 g) was then added, rendering the pH at approximately 6. Another 
portion of copper carbonate (1.2 g) was then added, raising the pH to -7.5. The 
undissolved residues were filtered off from the now azure blue solution. A solution of 
NaHC03 (10 mL, 1.3 mmol) was then added, followed by p-nitrophenyl-/V-methyl 
nicotinate (1.43 g, 3.7 mmol). After three min. a yellowish precipitation occurred, and 
the solution turned green. After 26 hours, the solution was acidified to pH 5 with HCl 
(1.2 M), causing C02(g) to be released. Diethyl ether extraction (4 x 60 mL) of p-
nitrophenol gave yellow ethereal phases, and the aqueous phase regained its azure blue 
color. The aqueous solution was then subjected to H2S(g) for 30 min., causing the 
solution to lose its colour while a brown-black precipitate of copper sulphide was 
formed. The The precipitate was filtered off and water was removed from the filtrate 
under reduced pressure. Recrystallisation of the crude product from ethanol failed. 
53 Murakami, Y.; Aoyama, Y.; Kikuchi, J.; Nishida, K. J. Chem. Soc., 1982, 104, 5189. 
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Water was then added to the crude product, and after acidification the solution was 
stirred with ion exchange resin (2.04 g, Dowex 50W-X8 (H)). The mixture was left for 
3-4 hours, after which the ion exchanger was packed in a column, and treated with 
ammonium hydroxide to release the product. Evaporation in vacuo gave the product as 
a crystalline substance. 
Mp: (lit.) 
'H NMR (400 MHz, D20) ô 9.1 (s, 1H), 8.8 (dd, 2H), 8.0 (t, 1H), 4.4 (s, 3H), 3.75 
(m, 1H), 1.8 (m, 6H) 
Pyridoxal analogues 
3-0-a4-isopropylidenepyridoxine (4) 
This substance was prepared according to the literature43. 
3-0-a4-isopropylideneisopyridoxal (5) 
This substance was prepared according to the literature55. 
3-0-a4-isopropylidene-a5-pyridoxyIideneacetic acid (6) 
This substance was prepared according to the literature42. 
3-0-a4-isopropylidene-a5-pyridoxylacetic acid (7) 
This substance was prepared according to the literature42. 
a5-pyridoxylacetic acid (8) 
This substance was prepared according to the literature42. 
54 Sharp, J.; Goseny, I.; Rowley, A. Practical Organic Chemistry, 1st ed., Chapman and Hall, 
Cornwall, 1989. 
55 Brooks, Jr., H. G.; Laakso, J. W.; Metzler, D. E. J. Heterocycl. Chem. 1966, 3, 126. 
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as-pyridoxalylacetic acid (9) 
This substance has been prepared but not analysed. 
a5-pyridoxalyIacetic acid ^-nitrophenol ester (10) 
This substance has not yet been prepared. 
Syntheses of the cyclohexapeptide project 
The syntheses described below start from substance 7, 3-0-a4-isopropylidene-a5-
pyridoxylacetic acid, described above. 
2-(3-0-oc4-isopropylidenepyridox-5-yI)-ethanol (12) 
This substance was prepared according to the literature42. 
3-0-a4-Isopropylidenepyridox-5-yl-ethyl-0-terM)utyldiphenylsilyl ether 
(13) 
This synthesis was based upon a general method reported in the literature44. (The 
reason for using TBDPS instead of TBDMS was that TBDMS was not able to 
withstand the TFAA-mediated rearrangment below.) To a stirred solution of 12 (3.66 
g, 15.4 mmol) in dry CH2C12 (150 mL) was added tert-butyl diphenyl silyl chloride 
(4.00 mL, 1 eq.), triethylamine (1 eq), and a catalytic amount of DMAP. The reaction 
mixture was stirred under nitrogen at ambient temperature for 12-14 h. The solvent was 
then removed in vacuo and the residue taken up in ether. The ethereal solution was 
filtered twice to remove triethyl amine hydrochloride, washed once with water, and 
dried (Na^OJ. The solvent was evaporated to yield 7.25 g of the pure product as an 
oil. Yield: 99%. 
'H NMR (400 MHz, CDC13) Ô 7.83 (s, 1H), 7.46 (d, 4H), 7.38 (m, 6H), 4.79 (s, 
2H), 3.69 (t, 2H), 2.51 (t, 2H), 2.39 (s, 3H), 1.75 (t, 2H), 1.54 (s, 6H), 1.05 (s, 9H) 
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3-O-oc4-Isopropylidenepyridox-5-yl-ethyl-0-terf-butyIdiphenyIsiIyI 
ether-l-oxide (14) 
This substance was prepared using a method from the literature42. To a stirred solution 
of 13 (5.07 g, 10.6 mmol) in dry CHC13 (50 mL) was added dry MCPBA (1.1 eq) 
dissolved in CHC13 (25 mL) at 0 °C. The reaction mixture was then stirred at r.t. for 2 
hours (until TLC indicated total consumption of reagents). The reaction mixture was 
then washed with NaHS03 (5%), NaHC03 (5%), and water. The solvent was removed 
in vacuo, and the crude oily product used without further purification in the next step. 
'H NMR (400 MHz, CDC13) 5 7.79 (s, 1H), 7.46 (d, 4H), 7.38 (m, 6H), 4.74 (s, 
2H), 3.69 (t, 2H), 2.51 (t, 2H), 2.39 (s, 3H), 1.75 (t, 2H), 1.54 (s, 6H), 1.05 (s, 9H) 
3-O-a4-IsopropyIidene-2'-hydroxy-norpyridox-5-yI-ethyl-0-/erf-
butyldiphenyl silyl ether (15) 
This substance was prepared using a method from the literature42. The crude TV-oxide 
14 from the former step was dissolved in CH2C12 (35 mL) and the solution cooled to 0 
°C. To the stirred solution TFAA (1 mL) was then added by syringe. Another portion of 
TFAA (2.5 mL) was added 5 minutes later. The reaction mixture was allowed to warm 
to room temperature and then stirred at r.t. for 8-14 h. MeOH (15 mL) was added and 
the reaction mixture stirred for 30 min, and then washed with Na2C03 (20%) and 
water. The solution was dried (NajSOJ and the solvent evaporated to yield 3.71 g of 
crystalline 15. Yield 90 % over both steps. 
When TBDMS was used as a protecting group, partial deprotection of the 5'-ethoxy 
group was evidenced in 'H NMR, approximately 50-60 % deprotection. 
'H NMR (400 MHz, CDC13) Ô 7.81 (s, 1H), 7.46 (d, 4H), 7.38 (m, 6H), 4.86 (s, 
2H), 4.74 (s, 2H), 3.68 (t, 2H), 2.51 (t, 2H), 1.75 (t, 2H), 1.54 (s, 6H), 1.05 (s, 
9H). 
3-0-a4-Isopropylidene-2-formyl-norpyridox-5-yI-ethyl-0-terf-
butyldiphenyl silyl ether (16) 
This substance was prepared using a method from the literature42. The alcohol 15 (3.70 
g, 9.0 mmol) was dissolved in CH2C12 (200 mL) and Mn02 (act.~90 %, ~7 eq, 15 g) 
was added. The heterogenous mixture was heated to reflux under nitrogen for 6 h (tic 
monitoring). The reaction mixture was the diluted with CH2C12 (50 mL) and treated 
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with Celite. Celite and Mn02 were removed by suction filtration. After evaporation of 
the solvent in vacuo, the crude aldehyde was used without further purification in the 
next step. 
'H NMR (400 MHz, CDC13) 6 10.24 (s, 1H), 8.18 (s, 1H), 7.46 (d, 4H), 7.38 (m, 
6H), 4.74 (s, 2H), 3.68 (t, 2H), 2.51 (t, 2H), 1.75 (t, 2H), 1.54 (s, 6H), 1.05 (s, 
9H). 
3-0-a4-Isopropylidene-2'-carboxyvinyl-norpyridox-5-yI-ethyI-0-terf-
butyldiphenyl silyl ether (17) 
This substance was prepared using a method from the literature42. The crude aldehyde 
16 was dissolved in pyridine (25 mL), and piperidine (1 mL) and malonic acid (0.94 g, 
9.0 mmol) was added. The reaction mixture was heated to 80 °C for 2 h and then stirred 
at r.t. overnight. Work-up was performed as with 5. Yield 3.11 g, 64 %. 
'H NMR (400 MHz, CDC13) 5 7.98 (s, 1H), 7.95 (d, 1H), 7.46 (d, 4H), 7.38 (m, 
6H), 6.95 (d, 1H), 4.74 (s, 2H), 3.68 (t, 2H), 2.51 (t, 2H), 1.75 (t, 2H), 1.54 (s, 
6H), 1.05 (s, 9H). 
3-0-a4-Isopropylidene-2-(3'-hydroxypropyl)-norpyridox-5-yI-ethyl-0-
terf-butyldiphenyl silyl ether (18) 
This substance was prepared using a method from the literature42. The acid 17 (1.0 g, 
1.9 mmol) was dissolved in dry THF (120 mL) and the solution added dropwise to a 
suspension of LiAlH4 (0.5 g) in dry THF (80 mL). The reaction mixture was stirred for 
lh at r.t., following which the excess hydride was destroyed with ethyl acetate 
followed by water. After extracting the aqueous phase with ethyl acetate, the combined 
organic phases were dried (Na^OJ and the sovent removed in vacuo, yielding the 
product as a yellow oil. Yield: 0.17 g (16 %) 
'H NMR (400 MHz, CDC13) 8 7.98 (s, 1H), 7.46 (d, 4H), 7.38 (m, 6H), 4.74 (s, 
2H), 3.68 (t, 2H), 3.05 (t, 3H), 2.71 (t, 2H), 2.51 (t, 2H), 1.65-1.75 (m, 4H), 1.54 
(s, 6H), 1.05 (s, 9H). 
(2R, 4S)-3-[benzyloxycarbonyI]-4-methyl-2-phenyl-l,3-oxazolidin-5-
one (19) 
This substance was prepared according to the literature47. 
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Alkylation of (2R, 4S)-3-[benzyloxycarbonyl]-4-methyl-2-phenyl-l,3-
oxazolidin-5-one (19) 
Thes reactions were performed according to the literature47. 
Alkylation of the 6/s-Iactim ether of cyclo-L-Val-L-Ala (21). 
This reaction was performed according to the literature48. 
(/f,/f)-(-)-Pseudoephedrine glycineamide (22) 
This substance was prepared according to the literature49. 
(/?,/f)-(-)-Pseudoephedrine alanineamide (23) 
This substance was prepared using methods reported in the literature49. N-t-Boc-
Alanine (500 mg, 2.64 mmol) and Et3N (442 |iL, 1.2 eq.) was dissolved in dry DCM 
(10 mL) at 0 °C and trimethylacetyl chloride (0.39 mL, 2.64 mmol) was added 
dropwise under vigorous stirring. After 30 min. a second portion of Et3N (442 |J,L, 1.2 
eq.) and (/?,/?)-(-)-pseudoephedrine (437 mg, 2.64 mmol) were added sequentially. 
The reaction mixture was stirred for 45 minutes and the volatiles were removed in 
vacuo. The reside was taken up in a methanol-water mixture (10 mL, 1:1) and cooled in 
an ice bath. Cone. Hcl (4 mL) was added, causing vigorous evolution of white fumes. 
After stirring for 3 h the methanol was removed in vacuo at 23 °C and the aqueous 
concentrate cooled in an ice bath while the pH was adjusted to to 14, using 50 % 
NaOH. The aqueous solution was extracted with DCM (4 x 10 mL) and the combined 
extracts were dried (IS^COj). The solution was filtered through Celite and the solvent 
removed to give white crystals that were recrystallised twice from toluene. The yield 
was 82.2 g 
Mp: 93.2-96.4 °C 
'H NMR (400 MHz, CDC13) Ô 7.3-7.4 (m, 5H), 4.65 (d, 1H), 4.60 (d, 1H), 4.0-4.1 
(m, 0.5H), 3.8 (d, 0.5H), 3.7 (d, 1H), 2.95 (s, 1.5H), 2.80 (s, 1.5H), 1.7 (s(broad), 
3H), 1.4 (d, 1.5H), 1.09 (d, 1.5H), 1.05 (d, 1.5H), 0.98 (d, 1.5H). 
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Alkylation of (Ä,Ä)-(-)-Pseudoephedrine glycineamide (22) 
This procedure was performed according to the literature49. 
Alkylation of (R ,R )-(-)-Pseudoephedrine alanineamide (23) 
This procedure was performed according to methods reported in the literature49. The 
attempted alkylations of 23 was perfomed exactly as with 22, but no product could be 
isolated. 
12.4. Cofactor model incorporation 
General procedure for cofactor model incorporation 
The peptide (~4 mg)was dissolved in 400 mL of Bis-Tris buffer at pH 5.9. The 
substrate was then added, and the mixture stirred on a shaking plate and left overnight. 
The salts in the mixture was removed by passing through a column of Sephadex GD-50 
size-exclusion gel. The peptide was then lyophilised and purified by HPLC. 
12.5. Kinetics and reaction studies 
General procedures 
The incorporation kinetics were all run in 50 mM sodium acetate buffer, at pH 4.96. 
The formation of p-nitrophenolate ion was monitored over time by UV spectrometer at 
320 nm. The kinetics were then analysed using Igor Pro. 
The kinetics studies on the reduction of the NAD+ analogues were all run in NaH2P04 
buffer (50 mM) at pH 7.0. The NAD+ analogue was dissolved in buffer, which was 
then deoxygenated by bubbling through nitrogen gas. The sodium dithionite and 
sodium carbonate mixture was then dissolved in buffer and the solution deoxygenated, 
following which the solutions were mixed, and the absorbance at 340 nm was studied 
over time with the UV spectrometer. The kinetics were then analysed using Igor Pro. 
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Background hydrolysis reaction of N-methylnicotininc acid p-
nitrophenyl ester 
Sodium acetate buffer (1.2 mL, 50 mM, pH 4.96) was transferred to an UV kuvette 
and tempered for 30 min. The NAD+ analogue (1.1 mg, -2.8 p.mol) was dissolved in 
water (1.0 mL) and from this solution, 80 jiL (0.19 mM) was added to the kuvette. The 
formation of p-nitrophenolate was monitored for several half-lives. 
Kinetics measurement of NAD+ analogue incorporation into RA-42 
RA-42 (1.2 mg, 27.4 |imol judging by an appr. 75 % peptide content) was dissolved in 
sodium acetate (1.2 mL, 50 mM, pH 4.96) and the solution was placed in an UV 
kuvette and tempered for 30 min. Approximately 1/5 of a molar equivalent of the NAD+ 
analogue was added to the kuvette, and the formation of p-nitrophenolate was 
monitored for several half-lives. The product was purified and analysed by ES-MS, in 
order to determine the extent of incorporation. 
Kinetics measurement of the reduction of 1-methylnicotinamide by 
sodium dithionite and sodium carbonate 
1-Methylnicotinamide (0.21 mg, 1.2 (imol) was dissolved in sodium phosphate buffer 
(400 |iL, 50 mM, pH 7.02) to give a 3 mM solution, and the solution deoxygenated by 
passing nitrogen gas through it for several minutes. Sodium dithionite (1.04 mg, 5 eq.) 
and sodium carbonate (0.64 mg, 5 eq) was then added under nitrogen flow, following 
which the formation of the 1,4-dihydronicotinamide was monitored at 340 nm for 
several half-lives. 
12.6. List of chemicals used in this investigation 
Chemical name Abbr. Grade Supplier 
Acetone 99% Riedel-de-Haen 
Acetone dimethyl acetal 98 % Aldrich 
L-Alanine Ala 99% Aldrich 
Ammonium fluoride NH4F 99% Riedel-de-Haen 
Benzaldehyde PhCHO 99% Aldrich 
Benzyl chloroformate CbzCl 95 % Aldrich 
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Butyllithium BuLi 1.6 M Aldrich 
Benzyl chloride BnCl 98 % Fluka 
tert-Butyl dimethyl silylchloride TBDMSCl 98 % Aldrich 
tert-Butyl diphenyl silylchloride TBDPSCl 98 % Aldrich 
Chloroform CHCI3 99.6 % Prolabo 
3-Chloroperbenzoic acid MCPBA 50-60 % Aldrich 
Copper carbonate 9 9 %  MCIB 
Cyclohexene 99.5 & Riedel-de-Haen 
Dichloromethane DCM 99 % J.T. Baker 
Dicyclohexyl carbodiimide DCC 99 % Lancaster 
Diethyl ether EtjO 99.5 % Riedel-de-Haen 
Diethylamine Et2NH 9 9 %  Riedel-de-Haen 
Diisopropyl ether (z-Pr)20 99 % Aldrich 
4-Dimethylamino pyridine DMAP 9 9 %  Aldrich 
Dimethylformamide DMF 9 9 %  Aldrich 
Ethanedithiol 99.5 % Lancaster 
Ethyl acetate EtOAc 99.5 % Riedel-de-Haen 
Fmoc-Ala-OH 99.9% Alexis 
Fmoc-Arg(Pmc)-OH 99.9% Alexis 
Fmoc-Asn(T rt)-OH 99.9% Alexis 
Fmoc-Asp(OtBu)-OH 99.9% Alexis 
Fmoc-Gln(Trt)-OH 99.9% Alexis 
Fmoc-Glu(OtBu)-OH 99.9% Alexis 
Fmoc-Gly-OH 99.9% Alexis 
Fmoc-His(Boc)-OH 99.9% Alexis 
Fmoc-Ile-OH 99.9% Alexis 
Fmoc-Leu-OH 99.9% Alexis 
Fmoc-Lys(Boc)-OH 99.9% Alexis 
Fmoc-Nle-OH 99.9% Alexis 
Fmoc-Phe-OH 99.9% Alexis 
Fmoc-Pro-OH 99.9% Alexis 
Fmoc-Val-OH 99.9% Alexis 
Hexane 95 % May & Baker 
Hydrogen peroxide H202 3 0 %  Riedel-de-Haen 
Isopropyl alcohol IPA 99.5 % Prolabo 
Lithium aluminum hydride LAH 9 9 %  Fluka 
Lithium diisopropylamide LDA 2 M (hexane) Aldrich 
Lithium bis(trimethylsilyl)amide LHMDS 1 M (THF) Aldrich 
52 
Malonic acid 98 % Lancaster 
Manganese (IV) oxide Mn02 90 % act. Fluka 
Methanol MeOH 99.8 % Merck 
Methyl iodide Mel 9 9 %  Fluka 
Methyllithium MeLi 1.4 M Aldrich 
1-Methyl nicotinamide Me-NAD 9 9 %  Lancaster 
Nicotinic acid 99.5 % Fluka 
Nicotinoyl chloride hydrochloride 97 % Aldrich 
p-Nitrophenol p NP  98 % Lancaster 
L-Ornithine hydrochloride 95 % EGA-Chemie 
n-Pentane 9 9 %  Riedel-de-Haen 
Piperidine 9 8 %  XXX??? 
Pyridine Pyr 9 9 %  Riedel-de-Haen 
Pyridoxal phosphate PPal 9 8 %  Aldrich 
Pyridoxine hydrochloride PolHCl 98 % Aldrich 
4-Pyrrolidinopyridine Prp 98 % Lancaster 
Pyruvic acid, sodium salt Prv-Na 9 9 %  Sigma 
Sodium 50 % in oil Aldrich 
Sodium carbonate 9 9 %  Fluka 
Sodium dithionite 97 % Riedel-de-Haen 
Sodium hydride NaH 55-65 % Fluka 
Sodium phospate, monobasic NaH2P04 98 % Aldrich 
Sodium sulphate Na2S04 9 9 %  Riedel-de-Haen 
Sulphuric acid H2S04 9 6 %  Labassco 
TBTU 9 9 %  Alexis 
Tetrahydrofuran THF 99.8 % Riedel-de-Haen 
Thioanisol 99.5 % Lancaster 
Thionyl chloride SOCl2 9 8 %  Fluka 
Triethylamine Et3N 98 % Aldrich 
Triethyl phosphono acetate 97 % Fluka 
Trifluoroacetic anhydride TFAA 98 % Fluka 
a,a,a-trifluoroacetophenone TFAB 9 9 %  Lancaster 
2,2,2-T rifluoroethanol TFE 9 9 %  Lancaster 
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På grund av upphovsrättsliga skäl kan vissa ingående delarbeten ej publiceras här. 
För en fullständig lista av ingående delarbeten, se avhandlingens början.
Due to copyright law limitations, certain papers may not be published here.
For a complete list of papers, see the beginning of the dissertation.



